medigraphic.com
ISSN 2683-1678 (Impreso)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2019, Número 2

<< Anterior Siguiente >>

Rev Latin Infect Pediatr 2019; 32 (2)


Farmacocinética de los antimicrobianos en la oxigenación por membrana extracorpórea (ECMO)

Mendoza FO, Castillo BJI, Salinas SJL, Saltigeral SP

Idioma: Español
Referencias bibliográficas: 53
Paginas: 69-77
Archivo PDF: 209.04 Kb.


FRAGMENTO

La terapia extracorpórea es el término general que se utiliza en referencia al apoyo mecánico temporal tras falla cardiaca o pulmonar. Cuando se usa en la Unidad de Cuidados Intensivos o en el Departamento de Urgencias para aumentar la oxigenación, ventilación o función cardiaca, se refiere como oxigenación por membrana extracorpórea (ECMO), la cual ha sido por más de 30 años la última esperanza para pacientes con falla cardiaca o respiratoria. De 2006 a la fecha ha aumentado su uso 400%.
Fue desarrollada en 1954 por el cirujano John Gibbon en búsqueda del tratamiento del embolismo pulmonar masivo; sin embargo, no fue hasta 1976 cuando Barlett et al. consiguieron el primer tratamiento exitoso en un adulto con síndrome de insuficiencia respiratoria aguda


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Mosier JM, Kelsey M, Raz Y et al. Extracorporeal membrane oxygenation (ECMO) for critically ill adults in the emergency department: history, current applications, and future directions. Crit Care. 2015; 19: 1-8. doi: 10.1186/s13054-015-1155-7.

  2. Bartlett RH. Extracorporeal life support: history and new directions. Semin Perinatol. 2005; 29: 2-7. doi: 10.1053/j.semperi.2005.02.002.

  3. Sherwin J, Heath T, Watt K. Pharmacokinetics and dosing of anti-infective drugs in patients on extracorporeal membrane oxygenation: a review of the current literature. Clin Ther. 2016; 1-19. doi: 10.1016/j.clinthera.2016.07.169.

  4. Shekar K, Fraser JF, Smith MT, Roberts JA. Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J Crit Care. 2012; 27 (6): 741.e9-741.e18. doi: 10.1016/j.jcrc.2012.02.013.

  5. Shekar K, Roberts JA, Mcdonald CI et al. Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. Crit Care. 2012; 16 (5): R194. doi: 10.1186/cc11679.

  6. Shekar K, Roberts JA, Barnett AG et al. Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models. Crit Care. 2015; 1-11. doi: 10.1186/s13054-015-1151-y.

  7. Shekar K, Roberts JA, Ghassabian S et al. Altered antibiotic pharmacokinetics during extracorporeal membrane oxygenation: cause for concern? J Antimicrob Chemother. 2013; 726-727. doi: 10.1093/jac/dks435.

  8. Mathot RAA. Determinants of drug absorption in different ECMO circuits. Intensive Care Med. 2010; 36: 2109-2116. doi:10.1007/s00134-010-2041-z.

  9. Rosen DA, Rosen R, Silvasi DL. In vitro variability in fentanyl absorption by different membrane oxygenators. J Cardiothorac Anesth. 1990; 4 (3): 332-335.

  10. Shekar K, Roberts JA, Smith MT, Fung YL, Fraser JF. The ECMO PK Project: an incremental research approach to advance understanding of the pharmacokinetic alterations and improve patient outcomes during extracorporeal membrane oxygenation Device Patient. BMC Anesthesiol. 2013;13: 7.

  11. Kozik DJ, Tweddell JS. Characterizing the inflammatory response to cardiopulmonary bypass in children. Ann Thorac Surg. 2006; 81: S2347-2354. doi: 10.1016/j.athoracsur.2006.02.073.

  12. Buck ML. Extracorporeal membrane oxygenation implications for drug therapy of neonates. Clin Pharmacokinet. 2003; 42 (5): 403-417.

  13. Wildschut ED, Ahsman MJ, Houmes RJ, Pokorna P, De Wildt SN, Mathot RA. Pharmacotherapy in neonatal and pediatric extracorporeal membrane oxygenation (ECMO). Curr Drug Metab. 2012; 13: 767-777.

  14. Jamal J, Economou CJ, Lipman J. Improving antibiotic dosing in special situations in the ICU: burns, renal replacement therapy and extracorporeal membrane oxygenation. Curr Opin Crit Care. 2012; 18 (5): 460-471. doi: 10.1097/MCC.0b013e32835685ad.

  15. Thalhammer F, Hörl WH. Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy. Clin Pharmacokinet. 2000; 39 (4): 271-279.

  16. Calderón CR et al. Infecciones durante la oxigenación de membrana extracorpórea. An Pediatr (Barc). 2018; 89 (2): 86-91.

  17. Hsu MS, Chiu KM, Huang YT, Kao KL, Chu SH, Liao CH. Risk factors for nosocomial infection during extracorporeal membrane oxygenation. J Hosp Infect. 2009; 73: 210-216.

  18. O’Neil JM, Schutze GE, Heulitt MJ, Simpson PM, Taylor BJ. Nosocomial infections during extracorporeal membrane oxygenation. Intensive Care Med. 2001; 27: 1247-1253.

  19. Bizarro MJ, Conrad SA, Kaufman DA, Rycus P. Infections acquried during extracorporeal membrane oxygenation in neonates, children, and adults. Pediatr Crit Care Med. 2011; 12: 1-5.

  20. Biffi S et al. Infections during extracorporeal membrane oxygenation: epidemiology, risk factors, pathogenesis and prevention. Int J Antimicrob Agents. 2017; 50: 9-16.

  21. Cashen K et al. Acquired infection during neonatal and pediatric extracorporeal membrane oxygenation. Perfusion. 2018; 33 (6): 472-482.

  22. Jin Na S et al. Blood stream infections in patients on venovenous extracorporeal membrane oxygenation for respiratory failure. Infection Control & Hospital Epidemiology. 2018; 39 (7): 871-874.

  23. Castagnola E et al. Epidemiology of infectious complications during extracorporeal membrane oxygenation in children. A single center experience in 46 runs. Pediatr Infect Dis J. 2018; 37 (7): 624-626.

  24. Santiago-Lozano MJ et al. Complicaciones infecciosas en niños tratados con oxigenación por membrana extracorpórea. Enferm Infecc Microbiol Clin. 2017.

  25. Graselli G. Nosocomial infections during extracorporeal membrane oxygenation: incidence, etiology and impact on patients’ outcome. Crit Care Med. 2017; 45 (10): 1726-1733.

  26. Steiner BCK, Stewart DL, Bond SJ, Hornung CA, Mckay VJ. Predictors of acquiring a nosocomial bloodstream infection on extracorporeal membrane oxygenation. J Pediatr Surg. 2001; 36 (3): 487-492. doi: 10.1053/jpsu.2001.21609.

  27. Amaker RD, Dipiro JT. Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 1996; 40 (5): 1139-1142.

  28. Buck ML, Pharm D. Vancomycin pharmacokinetics in neonates receiving. Pharmacotherapy. 1998; 5 (18): 1082-1086.

  29. Hoog M De, Mouton JW, Anker JN Van Den. Pharmacokinetics and administration regimens in neonates. Clin Pharmacokinet. 2004; 43 (7): 417-440.

  30. Pacifici GM, Ii IKA. Clinical pharmacokinetics of vancomycin in the neonate: a review. Clinics. 2012; 67 (7): 831-837. doi: 10.6061/clinics/2012(07)21.

  31. Mulla H, Pooboni S. Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation. Br J Clin Pharmacol. 2005; 60: 265-275. doi: 10.1111/j.1365-2125.2005.02432.x.

  32. Donadello K, Roberts JA, Cristallini S et al. Vancomycin population pharmacokinetics during extracorporeal membrane oxygenation therapy: a matched cohort study. Crit Care. 2014; 18: 4-13. doi: 10.1186/s13054-014-0632-8.

  33. Bertels RA, Semmekrot BA, Gerrits GP, Mouton JW. Serum concentrations of cefotaxime and its metabolite desacetyl-cefotaxime in infants and children during continuous infusion. Infection. 2008; 36 (5): 415-420. doi: 10.1007/s15010-008-7274-1.

  34. Ahsman MJ, Wildschut ED, Tibboel D, Mathot RA. Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 2010; 54 (5): 1734-1741. doi: 10.1128/AAC.01696-09.

  35. Cies JJ, Moore WS, Dickerman IIMJ et al. Pharmacokinetics of continuous-infusion meropenem in a pediatric patient receiving extracorporeal life support. Pharmacotherapy. 2014; 34 (10). doi: 10.1002/phar.1476.

  36. Shekar K, Fraser JF, Taccone FS, Welch S, Wallis SC, Mullany DV. The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study. Crit Care. 2014; 18: 1-9. doi: 10.1186/s13054-014-0565-2.

  37. Welsch C, Augustin P, Allyn J, Massias L, Montravers P, Allou N. Alveolar and serum concentrations of imipenem in two lung transplant recipients supported with extracorporeal membrane oxygenation. Transpl Infect Dis. 2015; 7 (Irb 00006477): 1-3. doi: 10.1111/tid.12327.

  38. Donadello K, Antonucci E, Cristallini S et al. β-Lactam pharmacokinetics during extracorporeal membraneoxygenation therapy: a case-control study. Int J Antimicrob Agents. 2014; doi: 10.1016/j.ijantimicag.2014.11.005.

  39. Macgowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother. 2003; 51: 17-25. doi: 10.1093/jac/dkg248.

  40. Rosa FG De, Corcione S, Baietto L et al. Pharmacokinetics of linezolid during extracorporeal membrane oxygenation. Int J Antimicrob Agents. 2013; 41 (6): 590-591. doi: 10.1016/j.ijantimicag.2013.01.016.

  41. Shekar K, Roberts JA, Mcdonald CI et al. Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study. Crit Care. 2015; 19: 1-8. doi:10.1186/s13054-015-0891-z.

  42. Gardner AH, Prodhan P, Stovall SH et al. Fungal infections and antifungal prophylaxis in pediatric cardiac extracorporeal life support. J Thorac Cardiovasc Surg. 2008; 143 (3): 689-695. doi: 10.1016/j.jtcvs.2011.12.001.

  43. Pluim T et al. The Morbidity and mortality of patients with fungal infections before and during extracorporeal membrane oxygenation support. Pediatr Crit Care. 2013; 13 (5): 82-89. doi: 10.1097/PCC.0b013e31824fbaf7.The.

  44. Daniell H. Pharmacokinetics and safety of fluconazole in young infants supported with extracorporeal membrane oxygenation. Pediatr Infect Dis J. 2012; 76 (October 2009): 211-220. doi: 10.1007/s11103-011-9767-z.Plastid.

  45. Watt KM, Gonzalez D, Benjamin DK et al. Fluconazole population pharmacokinetics and dosing for prevention and treatment of invasive candidiasis in children supported with extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 2015; 59 (7): 3935-3943. doi: 10.1128/AAC.00102-15.

  46. Spriet I, Annaert P, Meersseman P et al. Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation. J Antimicrob Chemother. 2009; 63 (4): 767-770. doi: 10.1093/jac/dkp026.

  47. Ruiz S, Papy E, Da Silva D et al. Potential voriconazole and caspofungin sequestration during extracorporeal membrane oxygenation. Intensive Care Med. 2009; 35 (1): 183-184. doi: 10.1007/s00134-008-1269-3.

  48. Koch BCP, Wildschut ED, Goede ALD, Hoog M De, Brüggemann RJM. Insufficient serum caspofungin levels in a paediatric patient on ECMO. Med Mycol Case Rep. 2013; 2 (1): 23-24. doi: 10.1016/j.mmcr.2012.12.006.

  49. Li C, Sun P, Dong Y et al. Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients. Antimicrob Agents Chemother. 2011; 55 (5): 2098-2105. doi: 10.1128/AAC.00905-10.

  50. Brüggemann RJM, Antonius T, Heijst A Van, Hoogerbrugge PM, Burger DM, Warris A. Therapeutic drug monitoring of voriconazole in a child with invasive aspergillosis requiring extracorporeal membrane oxygenation. Ther Drug Monit. 2008; 30 (6): 643-646. doi: 10.1097/FTD.0b013e3181898b0c.

  51. Mehta NM, Halwick DR, Dodson BL, Thompson JE, Arnold JH. Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment. Intensive Care Med. 2007; 33 (6): 1018-1024. doi: 10.1007/s00134-007-0606-2.

  52. Gonçalves-pereira J, Oliveira B. Antibiotics and extracorporeal circulation-one size does not fit all. Crit Care. 2014; 18: 1-2. doi: 10.1186/s13054-014-0695-6.

  53. Dzierba AL, Abrams D, Brodie D. Medicating patients during extracorporeal membrane oxygenation: the evidence is building. Crit Care. 2017; 21 (1): 66. doi:10.1186/s13054-017-1644-y.




2020     |     www.medigraphic.com